La Jolla Pharmaceutical Company - Company Profile
Powered by 
All the data and insights you need on La Jolla Pharmaceutical Company in one report.
$295
- Save hours of research time and resources with
our up-to-date La Jolla Pharmaceutical Company Strategy Report
- Understand La Jolla Pharmaceutical Company position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
La Jolla Pharmaceutical Company (La Jolla) discovers, develops and commercializes biopharmaceutical products for life-threatening diseases. The company’s major product includes the US FDA approved Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock and Xerava (eravacycline), is an injection of tetracycline class antibacterial for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its investigational product candidates include LJPC-0118 intended for the treatment of severe malaria and LJPC-401, a proprietary formulation of synthetic human hepcidin, an endogenous peptide hormone intended for the prevention of excessive iron accumulation in vital organs. The company sells Giapreza to hospitals in the US through a network of wholesale and specialty distributors. La Jolla is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
201 Jones Road, Suite 400, Waltham, Massachusetts, 02451
Website
www.lajollapharmaceutical.com
Telephone
1 617 7153600
No of Employees
61
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$75.7M
La Jolla Pharmaceutical Company premium industry data and analytics
Products and Services
| Products |
|---|
| Giapreza - Injection for Intravenous Infusion |
| Xerava – Injection for complicated intra-abdominal infections (cIAI) |
| Product Pipeline: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In July, the company entered into an agreement to be acquired by Innoviva. |
| 2021 | Contracts/Agreements | In January, the company announced that it has entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (PAION) for GIAPREZA (angiotensin II) and XERAVA (eravacycline) in Europe. |
| 2020 | Acquisitions/Mergers/Takeovers | In July, the company acquired Tetraphase Pharmaceuticals, Inc., a Pharmaceutical company. |
Competitor Comparison
| Key Parameters | La Jolla Pharmaceutical Company | PTC Therapeutics Inc | FibroGen Inc | Acceleron Pharma Inc | Agios Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Waltham | South Plainfield | San Francisco | Cambridge | Cambridge |
| State/Province | Massachusetts | New Jersey | California | Massachusetts | Massachusetts |
| No. of Employees | 61 | 1,402 | 592 | 312 | 389 |
| Entity Type | Private | Public | Public | Private | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kevin C. Tang | Chairman | Executive Board | 2014 | 54 |
| Larry Edwards | President; Chief Executive Officer; Director | Executive Board | 2020 | - |
| Michael Hearne | Chief Financial Officer | Senior Management | 2020 | - |
| Lakhmir S. Chawla, M.D. | Chief Medical Officer | Senior Management | 2015 | 50 |
| Stew Kroll | Chief Development Officer | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward